Read by QxMD icon Read

Lymphoma Outcomes

István Szegedi, Imre Gáspár, Katalin Gyurina, Zsuzsa Zele, Csongor Kiss
Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease...
December 12, 2018: Magyar Onkologia
Clémentine Sarkozy, Christiane Copie-Bergmand, Diane Damotte, Susana Ben-Neriah, Barbara Burroni, Jérome Cornillon, Richard Lemal, Camille Golfier, Bettina Fabiani, Catherine Chassagne-Clément, Marie Parrens, Charles Herbaux, Luc Xerri, Celine Bossard, Camille Laurent, Morgane Cheminant, Guillaume Cartron, Jose Cabecadas, Thierry Molina, Gilles Salles, Christian Steidl, Hervé Ghesquières, Anja Mottok, Alexandra Traverse-Glehen
Gray-zone lymphoma (GZL) with features intermediate between classic Hodgkin lymphoma (cHL) and large B-cell lymphoma (LBCL) was introduced as a provisional entity into the World Health Organization classification in 2008. However, as diagnostic criteria are imprecise, reliable identification of GZL cases remains challenging. Here, we describe the histopathologic features of 139 GZL cases from a retrospective Lymphoma Study Association (LYSA) study with the goal to improve classification accuracy. Inclusion criteria were based on literature review and an expert consensus opinion of the LYSA hematopathologist panel...
December 11, 2018: American Journal of Surgical Pathology
Everett J Moding, Ranjana Advani, Saul A Rosenberg, Richard T Hoppe
BACKGROUND AND PURPOSE: The role of irradiation to non-bulky and bulky sites of disease in advanced stage Hodgkin lymphoma is controversial. We aimed to review the long-term outcomes of patients treated with combined modality therapy to clarify the role of consolidative radiotherapy. MATERIALS AND METHODS: Patients with stage III or IV Hodgkin lymphoma treated with Stanford V chemotherapy and consolidative radiotherapy to initial sites of disease ≥5 cm were analyzed retrospectively to determine patient outcomes, patterns of failure, and factors associated with treatment failure...
December 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Zhenyang Gu, Lu Wang, Quanshun Wang, Honghua Li, Jian Bo, Shuhong Wang, Yu Zhao, Fei Li, Chunji Gao, Daihong Liu, Wenrong Huang
There was limited information about the efficacy of myeloablative allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in non-complete remission (non-CR) patients with relapsed/refractory peripheral T cell lymphomas (PTCLs). We conducted a retrospective study of 21 consecutive non-CR patients with relapsed/refractory PTCLs who received myeloablative allo-PBSCT between January 2008 and June 2016. The median follow-up of survivors was 46.5 months (range, 14-105 months). The estimated 3-year relapse rate was 24% (95% CI, 9 to 43%)...
December 11, 2018: Annals of Hematology
John J Moore, Jennifer C Massey, Carole D Ford, Melissa L Khoo, John J Zaunders, Kevin Hendrawan, Yael Barnett, Michael H Barnett, Kain A Kyle, Robert Zivadinov, Kris C Ma, Sam T Milliken, Ian J Sutton, David D F Ma
BACKGROUND: Autologous haematopoietic stem cell transplantation (AHSCT) has been explored as a therapeutic intervention in multiple sclerosis (MS) over the last two decades; however, prospective clinical trials of the most common myeloablative conditioning regimen, BEAM, are limited. Furthermore, patient selection, optimal chemotherapeutic regimen and immunological changes associated with disease response require ongoing exploration. We present the outcomes, safety and immune reconstitution (IR) of patients with active, treatment refractory MS...
December 11, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
Deyu Sun, Yi Mu, Haozhe Piao
BACKGROUND: Glioma is the most prevalent malignant tumor in human central nervous systems. Recently, the development of resistance to radiotherapy in glioma patients markedly vitiates the therapy outcome. MiR-153-3p has been reported to be closely correlated with tumor progression, but its effect and molecular mechanism underlying radioresistance remains unclear in glioma. METHODS: The expression of miR-153-3p was determined in radioresistant glioma clinical specimens as well as glioma cell lines exposed to irradiation (IR) using quantitative real-time PCR...
December 11, 2018: Biological Research
Richard J Lin, Caleb Ho, Patrick D Hilden, Juliet N Barker, Sergio A Giralt, Paul A Hamlin, Ann A Jakubowski, Hugo R Castro-Malaspina, Kevin S Robinson, Esperanza B Papadopoulos, Miguel-Angel Perales, Craig S Sauter
TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60-88] and 61% (95% CI 43-75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively...
December 11, 2018: British Journal of Haematology
Gottfried von Keudell, Anas Younes
Hodgkin Lymphoma (HL) is a B-cell lymphoproliferative disorder with an excellent prognosis for the majority of patients who are treated with multi-agent chemotherapy, with or without radiation. A subset of patient, however, does not respond to therapy or relapses after accomplishing an initial response. Their outcome is poor and new treatment strategies are urgently needed for this patient population. Recent advances in the understanding of the tumour biology of HL and its microenvironment have ushered a new era of targeted- and immuno-therapies with remarkable activity...
December 11, 2018: British Journal of Haematology
Maxens Decavèle, Isabelle Rivals, Clémence Marois, Marie Cantier, Nicolas Weiss, Léa Lemasle, Hélène Prodanovic, Khe Hoang-Xuan, Ahmed Idbaih, Thomas Similowski, Alexandre Demoule
PURPOSE: Acute respiratory failure (ARF) is common and potentially fatal in patients with primary malignant brain tumors (PMBT). However, few data are available regarding its precipitating factors and prognosis. We sought to: (1) compare the causes of ARF and the outcome between patients with PMBT and patients with other peripheral solid tumors (PST), (2) identify the factors influencing ICU survival in PMBT patients. METHODS: Two-center retrospective case-control study from March 1996 to May 2014...
December 7, 2018: Journal of Neuro-oncology
Daisuke Minakata, Shin-Ichiro Fujiwara, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shin-Ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Tsukasa Ohmori, Yoshinobu Kanda
We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemia (n = 48), acute lymphoblastic leukemia (n = 25), and non-Hodgkin lymphoma (n = 54)] with DIC, who were diagnosed according to Japanese Ministry of Health, Labour and Welfare criteria and treated with SPIs [FOY (n = 55) and FUT (n = 72)] at our hospital from 2006 to 2015...
December 8, 2018: International Journal of Hematology
Awachana Jiamsakul, Mark Polizzotto, Stephane Wen-Wei Ku, Junko Tanuma, Eugenie Hui, Romanee Chaiwarith, Sasisopin Kiertiburanakul, Anchalee Avihingasanon, Evy Yunihastuti, Nagalingeswaran Kumarasamy, Penh Sun Ly, Sanjay Pujari, Rossana Ditangco, Cuong Duy Do, Tuti Parwati Merati, Pacharee Kantipong, Fujie Zhang, Kinh Van Nguyen, Adeeba Kamarulzaman, Jun Yong Choi, Benedict Lh Sim, Oon Tek Ng, Jeremy Ross, Wingwai Wong
BackgroundHaematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence, risk factors for, and outcomes of haematological and non-haematological malignancies in PLHIV in Asia.MethodsIncidence of malignancy after cohort enrolment was evaluated. Factors associated with development of haematological and non-haematological malignancy were analysed using competing risk regression and survival time using Kaplan-Meier.ResultsOf 7455 patients, 107 patients (1%) developed a malignancy: 34 (0...
November 29, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
Aurélie Schwing, Christelle Pomares, Alissa Majoor, Laurent Boyer, Pierre Marty, Grégory Michel
Given the prevalence of cancer and leishmaniasis worldwide, the presence of these two pathologies in the same tissue sample may be merely fortuitous. The clinical outcome of both diseases is under the control of innate and adaptive immunity, and in both cases these progressive diseases are characterized by an impaired host Th1 response. As a consequence, the Th2 cytokine microenvironment occurring in progressive leishmaniasis may potentially promote tumor cell proliferation and vice versa. On the other hand, clinical aspects of subclinical cutaneous or visceral leishmaniasis sometimes closely resemble those observed in various neoplasms thus leading to misdiagnosis...
December 7, 2018: Acta Tropica
Shuangshuang Fu, Michael Wang, Ruosha Li, David R Lairson, Bo Zhao, Xianglin L Du
BACKGROUND: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. METHODS: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995-1998, P1), rituximab + chemotherapy (1999-2004, P2), bortezomib and HyperCVAD (2005-2008, P3), bendamustine and Nordic regimen (2009-2013, P4)...
December 5, 2018: Cancer Epidemiology
Kevin H Hall, Kelly Valla, Christopher R Flowers, Jonathon B Cohen
INTRODUCTION: Intrathecal chemoprophylaxis is often administered to patients with diffuse large B-cell lymphoma (DLBCL) to lower the rates of central nervous system (CNS) relapse, although its benefit has not been well-described. Prognostic models, including the CNS-International Prognostic Index (IPI), have been developed to aid in identifying patients at highest risk for CNS relapse. PATIENTS AND METHODS: We evaluated 112 patients diagnosed with DLBCL from 2009 to 2016 at Emory Healthcare and classified them as high (n = 44) or low risk (n = 68) for CNS relapse and compared CNS prophylaxis rates and relapse rates between groups...
November 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
Marie-Louise Lovgren, Julia J Scarisbrick
Mycosis fungoides (MF) represents the majority of the primary cutaneous T-cell lymphomas (CTCL). Most have early stage MF with localised patches and plaques, which has a favourable survival outcome, but nearly a quarter progress to late stage with tumours, erythroderma, and systemic involvement. Management is based on stage directed treatment with early stage MF (IA-IIA) using skin directed therapies (SDTs), including topical corticosteroids (TCS), chlormethine or retinoids, phototherapy, and radiotherapy (localised or total skin electron beam therapy)...
November 28, 2018: Chinese Clinical Oncology
William T Johnson, Reetu Mukherji, Saritha Kartan, Neda Nikbakht, Pierluigi Porcu, Onder Alpdogan
Mycosis fungoides and Sézary syndrome encompass over 70% of all cases of cutaneous T-cell lymphoma (CTCL). While early stage disease has excellent long-term survival rates, advanced stage disease (IIB-IV) carries a poor prognosis with a median 5-year overall survival rate of approximately 50%. Early stage and advanced stage disease have different treatment algorithms with systemic therapy being indicated upfront in the later. The role of allogeneic hematopoietic stem cell transplant (HSCT) has gained considerable interest in recent years as a treatment option for CTCL given the increasingly promising long-term outcomes in an otherwise incurable disease...
October 19, 2018: Chinese Clinical Oncology
Mudit Chowdhary, Andrew Song, Nicholas G Zaorsky, Wenyin Shi
Cutaneous T-cell lymphoma is a rare group of malignancies characterized by the proliferation of CD4+ T-cells, of which mycosis fungoides (MF) is the predominant subtype. The neoplastic lymphocytes of MF are extremely radiosensitive and even low doses of radiation can produce excellent responses. As such, radiotherapy (RT) is considered to be the most efficacious single agent treatment option for MF. Total skin electron beam therapy (TSEBT) is a special RT technique that allows for homogenous irradiation of the entire skin...
September 17, 2018: Chinese Clinical Oncology
Teresa M Waters, Cameron M Kaplan, Ilana Graetz, Mary M Price, Laura A Stevens, Barbara L McAneny
PURPOSE: We examined whether the Community Oncology Medical Home (COME HOME) program, a medical home program implemented in seven community oncology practices, was associated with changes in spending and care quality. PATIENTS AND METHODS: We compared outcomes from elderly fee-for-service Medicare beneficiaries diagnosed between 2011 and 2015 with breast, lung, colorectal, thyroid, or pancreatic cancer, lymphoma, or melanoma and served by COME HOME practices before and after program implementation versus similar beneficiaries served by other geographically proximate oncologists...
December 5, 2018: Journal of Oncology Practice
Chulin Sha, Sharon Barrans, Francesco Cucco, Michael A Bentley, Matthew A Care, Thomas Cummin, Hannah Kennedy, Joe S Thompson, Rahman Uddin, Lisa Worrillow, Rebecca Chalkley, Moniek van Hoppe, Sophia Ahmed, Tom Maishman, Josh Caddy, Anna Schuh, Christoph Mamot, Catherine Burton, Reuben Tooze, Andrew Davies, Ming-Qing Du, Peter W M Johnson, David R Westhead
PURPOSE: Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt lymphoma is well known. Conventional cytogenetics identifies some patients with rearrangements of MYC and BCL2 and/or BCL6 (double-hit lymphomas) who are increasingly treated with more intensive chemotherapy, but a more biologically coherent and clinically useful definition of this group is required. PATIENTS AND METHODS: We defined a molecular high-grade (MHG) group by applying a gene expression-based classifier to 928 patients with DLBCL from a clinical trial that investigated the addition of bortezomib to standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy...
December 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Daisuke Ennishi, Aixiang Jiang, Merrill Boyle, Brett Collinge, Bruno M Grande, Susana Ben-Neriah, Christopher Rushton, Jeffrey Tang, Nicole Thomas, Graham W Slack, Pedro Farinha, Katsuyoshi Takata, Tomoko Miyata-Takata, Jeffrey Craig, Anja Mottok, Barbara Meissner, Saeed Saberi, Ali Bashashati, Diego Villa, Kerry J Savage, Laurie H Sehn, Robert Kridel, Andrew J Mungall, Marco A Marra, Sohrab P Shah, Christian Steidl, Joseph M Connors, Randy D Gascoyne, Ryan D Morin, David W Scott
PURPOSE: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. PATIENTS AND METHODS: We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 with HGBL-DH/TH- BCL2, to define a gene expression signature that distinguishes HGBL-DH/TH- BCL2 from other GCB-DLBCLs...
December 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"